Compare JetBlue Airways Corporation (JBLU) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JetBlue Airways Corporation vs GeneDx Holdings Corp — how do they compare? JetBlue Airways Corporation trades at $5.4 (market cap $2.03B), while GeneDx Holdings Corp trades at $60.8 (market cap $1.80B). The key difference: JetBlue Airways Corporation and GeneDx Holdings Corp are close in size by market cap, and JetBlue Airways Corporation is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| JBLU | WGS | |
|---|---|---|
Market Cap | $2.03B | $1.80B |
Sector | Industrials | Technology |
52-Week High | $6.46 | $167.51 |
52-Week Low | $4.03 | $34.51 |
Enterprise Value | $9.19B | $1.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JetBlue (JBLU) trades at $5.45, up 0.55% today, with technical indicators showing a neutral bias despite recent earnings misses. The airline reported a net loss of $602 million in 2025 with negative profit margins, though valuation metrics like P/S of 0.22 appear attractive. Recent news highlights expansion at Fort Lauderdale and new payment partnerships, while analyst consensus remains cautious with a $5.12 price target.
JBLU faces significant challenges with persistent losses and high debt levels, though strategic expansions and cost management efforts provide some optimism. The stock trades near analyst targets with mixed sentiment, requiring careful monitoring of upcoming Q2 2026 earnings and fuel cost trends for directional clarity.
GeneDx Holdings (WGS) trades at $60.65, down 4.46% amid a bearish technical signal and negative profitability. Recent earnings showed a Q1 2026 miss after two prior beats, with revenue growth but widening losses projected for 2026. The stock faces significant headwinds from multiple securities class action lawsuits alleging misrepresentations, with a deadline of August 3, 2026.
Despite a high analyst buy consensus (90.9%) and a $75.40 price target implying 24% upside, risks are elevated due to litigation, negative margins, and a high EV/EBITDA of 161.17. The upcoming Q2 2026 results on August 3 will be critical for investor confidence, but the legal overhang and fundamental challenges suggest cautious near-term outlook.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
